Mycobacterial cell wall biosynthesis: a multifaceted antibiotic target

KATHERINE A. ABRAHAMS and GURDYAL S. BESRA*

Institute of Microbiology and Infection, School of Biosciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK

(Received 7 September 2016; revised 2 November 2016; accepted 8 November 2016; first published online 15 December 2016)

SUMMARY

*Mycobacterium tuberculosis* (*Mtb*), the etiological agent of tuberculosis (*TB*), is recognized as a global health emergency as promoted by the World Health Organization. Over 1 million deaths per year, along with the emergence of multi- and extensively-drug resistant strains of *Mtb*, have triggered intensive research into the pathogenicity and biochemistry of this microorganism, guiding the development of anti-TB chemotherapeutic agents. The essential mycobacterial cell wall, sharing some common features with all bacteria, represents an apparent ‘Achilles heel’ that has been targeted by TB chemotherapy since the advent of TB treatment. This complex structure composed of three distinct layers, peptidoglycan, arabinogalactan and mycolic acids, is vital in supporting cell growth, virulence and providing a barrier to antibiotics. The fundamental nature of cell wall synthesis and assembly has rendered the mycobacterial cell wall as the most widely exploited target of anti-TB drugs. This review provides an overview of the biosynthesis of the prominent cell wall components, highlighting the inhibitory mechanisms of existing clinical drugs and illustrating the potential of other unexploited enzymes as future drug targets.

Key words: tuberculosis, cell wall, peptidoglycan, arabinogalactan, mycolic acids, antibiotics.

INTRODUCTION

*Mycobacterium tuberculosis* (*Mtb*), the causative agent of tuberculosis (*TB*), is regarded as the world’s most successful pathogen (Hingley-Wilson *et al.* 2003). Responsible for an estimated 1·4 million deaths and 10·4 million new cases of TB, including 480 000 new cases of multi-drug resistant (MDR)-*TB* in 2015 (World Health Organization, 2016), *Mtb* remains a global health emergency as declared by the World Health Organization (WHO) (World Health Organization, 2014). New chemotherapeutic agents to complement or replace existing front-line treatment regimens are urgently required to reduce treatment time (currently 6-month course) and to combat the increasing threat by this microorganism.

The distinguishing feature of mycobacteria, the complex cell wall, is a well-recognized drug target. The cell wall is common to all bacteria, both Gram-positive and Gram-negative, but can have vast differences in terms of the biochemical and structural features. Over the past decade, extensive research into cell wall assembly, aided by whole-genome sequencing, has led to an increased understanding of mycobacterial cell wall biosynthesis. This has promoted further exploration into the discovery and development of chemotherapeutic agents (from an enzymatic and phenotypic perspective) directed against the synthesis of this unique macromolecule structure in *Mtb*. The *Mtb* cell envelope is an expandable structure and is summarized in Fig. 1. The inner membrane phospholipid bilayer contains glycolipids that extend into the periplasmic space. The essential core cell wall structure is composed of three main components: a cross-linked polymer of peptidoglycan, a highly branched arabinogalactan polysaccharide, and long-chain mycolic acids. Intercalated into the mycolate layer are solvent-extractable lipids including non-covalently linked glycolipids and inert waxes, forming the outer membrane. The capsule forms the outermost layer and is mainly composed of proteins and polysaccharides. The lipid- and carbohydrate-rich layers of the cell wall serve not only as a permeability barrier, providing protection against hydrophilic compounds, but also are critical in pathogenesis and survival. It is these traits that make the biosynthesis and assembly of the cell wall components attractive drug targets. This review focuses on the synthesis of the key cell wall components, highlighting previously validated targets and the ongoing drug discovery efforts to inhibit other essential enzymes in mycobacterial cell wall biosynthesis.

PEPTIDOGLYCAN

Peptidoglycan is a major component of the cell wall of both Gram-positive and Gram-negative bacteria (Vollmer *et al.* 2008). It is a polymer of alternating *N*-acetylmuramic acid and *N*-acetylglicosamine and...
residues via \( \beta(1 \rightarrow 4) \) linkages with side chains of amino acids cross-linked by transpeptide bridges (Brennan and Nikaido, 1995). Mycobacterial peptidoglycan has a number of unique features that diversifies the cell wall from the typical structure including \( \text{N}-\)glycolyl- and \( \text{N}-\)acetyl-muramic acid residues (Mahapatra et al. 2005a), amidation of the carboxylic acids in the peptide stems (Mahapatra et al. 2005b) and additional glycine or serine residues (Vollmer et al. 2008). The function of peptidoglycan is not only to provide shape and rigidity, but it is responsible for counteracting turgor pressure and hence it is essential for growth and survival (Vollmer et al. 2008). Peptidoglycan is unique to bacterial cells, and it is this property that has led to numerous enzymes involved in its synthesis to be targeted by potent antibiotics, with others representing attractive targets in the development of future antibiotics.

**PEPTIDOGLYCAN BIOSYNTHESIS**

The biosynthesis of peptidoglycan is summarized in Fig. 2. The first committed step is the generation of uridine diphosphate-\( \text{N}-\)acetylglucosamine (UDP-GlcNAc). This is catalysed by the acetyltransferase and uridylyltransferase activities of GlmU (Zhang et al. 2009), where first the acetyl group from acetyl-CoA is transferred to glucosamine-1-phosphate (GlcN-1-P) to produce \( \text{N}-\)acetylglucosamine-1-phosphate (GlcNAc-1-P). Secondly, uridine-5′-monophosphate from UTP is transferred to GlcNAc-1-P to yield UDP-GlcNAc (Zhang et al. 2009). The abundance of GlcNAc-1-P in eukaryotes (Mio et al. 1998) and the functional similarity of the GlmU uridyltransferase with human enzymes (Penneff et al. 2001) makes this domain an unsuitable drug target (Rani and Khan, 2016). However, the absence of GlcN-1-P from humans makes the acetyltransferase domain a potential target (Mio et al. 1998). Efforts to identify inhibitors of this domain are underway (Tran et al. 2013). A substrate analogue of GlcN-1-P has been designed and exhibits inhibitory effect against GlmU, providing a candidate for further optimization (Li et al. 2011).

The next step involves the generation of the UDP-\( \text{N}-\)acetylMuramic acid (UDP-MurNAc)-pentapeptide, which is synthesized in a sequential pathway catalysed by the Mur ligases A–F (Barreteau et al. 2008), whereby most of the \( \text{Mtb} \) genes have been found through homology. MurA, a UDP-\( \text{N}-\)acytylglucosamine 1-carboxyvinyltransferase, and MurB, a UDP-\( \text{N}-\)acytylenolpyruvoylglucosamine reductase, are involved in generating UDP-MurNAc from UDP-GlcNAc, by the addition of the enoylpyruvyl moiety of PEP, followed by reduction to a lactoyl ether moiety via NADPH. At this point, NamH, a
UDP-N-acetylmuramic acid hydroxylase, hydroxylates UDP-MurNAc to UDP-N-glycolylmuramic acid (UDP-MurNGlyc), providing both types of UDP-muramyl substrates; \( \text{Mtb} \) cell walls are dominated by the latter (Mahapatra et al. 2005). This structural modification is unique to mycobacteria (and closely related genera) and is considered to increase the intrinsic strength of peptidoglycan, by potentially alleviating susceptibility to lysozyme and providing sites for additional hydrogen bonding (Raymond et al. 2005). Inhibitors of \( \text{Mtb} \) MurA and MurB are yet to be discovered. Whilst the natural product, broad spectrum antibiotic, fosfomycin, targets Gram-negative MurA, the critical residue for inhibition is absent in \( \text{Mtb} \), providing intrinsic resistance against this antibiotic (Kim et al. 1996). Consequently, an inhibitor with a new mode of action is required to target \( \text{Mtb} \) MurA. A limited number of inhibitors have been reported against MurB. Molecular dynamics and docking studies of existing MurB inhibitors (3,5-dioxopyrazolidine derivatives) onto the \( \text{Mtb} \) MurB structure reveal the potential potent activity of these compounds, which can be used to guide future structure-based drug design (Kumar et al. 2011). Inhibitors of NamH have not been documented; \( \text{namH} \) is not essential in \( \text{Mycobacterium smegmatis} \), and therefore is not conducive to a characteristic target property. However, gene deletion results in a strain hypersusceptible to \( \beta \)-lactam antibiotics and lysozyme and therefore inhibitors of NamH could potentiate the effect of \( \beta \)-lactams (Raymond et al. 2005).

The pentapeptide chain is incorporated onto the UDP-MurNAc/Glyc substrates by the successive addition of amino acid residues L-alanine, D-isoglutamate, meso-diaminopimelate (m-DAP) and D-alanyl-D-alanine [generated by the D-Ala: D-Ala ligase (Ddl)] by the ATP-dependent Mur ligases C-F respectively (Munshi et al. 2013). This results in the muramyl-pentapeptide product, UDP-MurNAc/Glyc-L-Ala-D-isoGlu-m-DAP-D-Ala-D-Ala, also known as Park’s nucleotide (Kurosu et al. 2007). Despite the different amino acid specificities, the four ligases share common properties: the reaction mechanism; six invariant ‘Mur’ residues; an ATP-binding consensus; three-dimensional structural domains (Barreteau et al. 2008). Due to these similarities, it is plausible that a single inhibitor could target more than one Mur ligase and such inhibitors have been reported in the literature (Tomasic et al. 2010). Numerous small molecule inhibitors of the Mur

![Diagram of inhibitors targeting peptidoglycan biosynthesis](https://www.cambridge.org/core/fig/118/1181ee5d5641b5f1194e2a25e8c0564c)
ligases have been discovered and are the subject of an extensive review (Hrast et al. 2014). In most cases, the inhibitors were identified from high-throughput screening (HTS) campaigns of compound libraries employing in vitro kinetic assays. These types of in vitro screening methods are limited in use against Mtb Mur ligases given that only MurC and MurE have been biochemically characterized (Mahapatra et al. 2000; Lä et al. 2011). This dictates the next rational step towards the target-based discovery of Mur ligase inhibitors. Ddl is the target of D-cycloserine (Bruning et al. 2011), a second-line drug used in the treatment of TB, and is at the cornerstone of treatment for MDR and extensively drug resistant (XDR)-TB. D-cycloserine acts as a structural analogue of D-alanine (D-Ala) against the binding of either D-Ala to Ddl (Prosser and de Carvalho, 2013a, b).

The first membrane-anchored peptidoglycan precursor is generated by the translocation of Park’s nucleotide to decaprenyl phosphate (C50-P), catalysed by MurX (also known as MraY), forming Lipid I (Kurosu et al. 2007). There are a number of nucleoside-based complex natural products that inhibit MurX, including muraymycin, liposidomycin, caprazamycin and capuramycin (Dini, 2005). Capuramycin and derivatives exhibit killing in vitro and in vivo and more significantly, analogues of capuramycin have been shown to kill non-replicating Mtb, a feature not common to the majority of cell wall biosynthesis inhibitors (Koga et al. 2004; Reddy et al. 2008; Nikonenko et al. 2009; Siricilla et al. 2015). Significantly, the analogue SQ641 is in preclinical development (http://www.newtbdrugs.org).

The final intracellular step of peptidoglycan synthesis is performed by the glycosyltransferase, MurG. A β(1 → 4) linkage between GlcNAc (from UDP-GlcNAc) and MurNAc/Glyc of Lipid I is formed, leading to the generation of Lipid II, the monomeric building block of peptidoglycan (Mengin-Lecreulx et al. 1991). A library of translocation state mimics have been designed for Escherichia coli MurG, and tested against Mtb MurG with partial success, one being the first inhibitor identified against the Mtb enzyme (Trunkfield et al. 2010).

The enzyme catalysing the translocation of Lipid II across the plasma membrane has been the subject of much debate. To date, there is evidence for two different enzymes with ‘flipase’ activity: MurJ and FtsW (Ruiz, 2008, 2015; Mohammadi et al. 2011, 2014; Sham et al. 2014). Further biochemical characterization is required to confirm the identification of the ‘flipase’. Inhibitors against this enzyme would be expected to exhibit broad-spectrum activity, targeting a vital activity in all bacteria.

Following translocation across the plasma membrane, Lipid II is polymerized by the monofunctional and bifunctional Penicillin-binding proteins (PBPs) (Sauvage et al. 2008). Bifunctional PBPs (PonA1/PBP1 and PonA2/PBP2) possess transglycosylase and transpeptidase domains. The former domain is responsible for linking the disaccharide building blocks of Lipid II to the pre-existing glycan chains (with the concomitant release of decaprenyl pyrophosphate), whereas the latter domain catalyses the formation of the classical (3 → 4) cross-links, between m-DAP and D-Ala of the adjacent pentapeptide chains, with the cleavage of the terminal D-Ala. D,D-transpeptidation and D,D-carboxypeptidation is performed by the monofunctional PBPs, both resulting in the cleavage of the terminal D-Ala of the peptide stem (Goffin and Ghysen, 2002). Only 20% of the cross-links in Mtb peptidoglycan are (3 → 4) (Kumar et al. 2012). The majority are (3 → 3) between two tetrapeptide stems, with the release of the fourth position D-Ala (Lavollay et al. 2008). This reaction is catalysed by the L,D-transpeptidases, with D,D-carboxypeptidation as a prerequisite activity. The L,D-transpeptidases are structurally unrelated to PBPs, with different active site residues (cysteine and serine, respectively) (Mainardi et al. 2005; Biarrotte-Sorin et al. 2006). The β-lactam antibiotics have been used in the treatment of bacterial infections for nearly a century, and gave rise to the discovery of their target, the PBPs. The L,D-transpeptidases are resistant to most β-lactam antibiotics, except the carbapenems (Dubee et al. 2012). Until recently, β-lactams were not considered for use in the treatment of TB, due to the expression of a broad-spectrum β-lactamase, BlaC. However, it has been shown that BlaC is irreversibly inactivated by clavulanic acid, yet hydrolyses carbapenems at a low rate (Hugonnet et al. 2009).

Combined treatment of the β-lactam with the β-lactamase inhibitor has been shown to be bactericidal against both replicating and non-replicating forms of Mtb, and combinations are now being explored in clinical trials (Hugonnet et al. 2009; Rullas et al. 2015). A well-documented inhibitor of the transglycosylase of PBPs, moenomycin (van Heijenoort et al. 1987), a natural product glycolipid, is yet to have proven efficacy against Mtb.

The inhibitors discussed thus far directly target the enzymes involved in peptidoglycan biosynthesis. There are, however, other antibiotics that act on the peptidoglycan precursors. For example, the glycopeptides, vancomycin and teicoplanin, bind to the D-Ala-D-Ala terminus of the pentapeptide stem, preventing polymerization reactions (Reynolds, 1989). Members of the lanthibiotic family of antibiotics, such as nisin, interact with the pyrophosphate moiety of Lipid II, forming a pore in the cytoplasmic membrane, but also inhibiting peptidoglycan biosynthesis (Wiedemann et al. 2001). The lipoglycodelpептид peptide ramoplanin inhibits the action of MurG by binding to Lipid I. Ramoplanin also binds to Lipid II, preventing its polymerization (Lo et al. 2000).
ARABINOGLACTAN

The major cell wall polysaccharide, arabinogalactan (Fig. 1), as the name suggests, is composed of galactose and arabinose sugar residues, in the furanose (\(\beta\)) ring form (Gal\(\beta\)) (McNeil et al. 1987). Arabinogalactan is attached to peptidoglycan via a single linker unit (McNeil et al. 1990). The galactan component is a linear chain of approximately 30 alternating 5- and 6-linked \(\beta\)-D-Gal\(\beta\) residues (Daffe et al. 1990). Three highly branched arabinan chains, consisting of approximately 30 Ara\(\beta\) residues, are attached to the galactan chain (Besra et al. 1995). The non-reducing termini of the arabinan chains act as an attachment site for mycolic acids, succinyl and galactosamine (D-GalN) moieties (Draper et al. 1997; Bhamidi et al. 2008).

ARABINOGLACTAN BIOSYNTHESIS

Arabinogalactan biosynthesis is illustrated in Fig. 3. The first committed step begins in the cytoplasm and proceeds by the formation of the linker unit connecting peptidoglycan to arabinogalactan, which is initiated by WecA, a GlcNAc-1-P transferase (Jin et al. 2010). This enzyme catalyses the transfer of GlcNAc-1-P to C\(\alpha\)-P. WbbL, a rhamnosyltransferase catalyses the transfer of L-rhamnose (L-Rha) from dTDP-L-Rha to position 3 of C\(\alpha\)-P-P-GlcNAc-L-Rha, forming the linker unit (McNeil et al. 1990; Mills et al. 2004). WecA has been identified as the target of caprazamycin derivatives, such as CPZEN-45, with the original nucleoside antibiotic shown to target MraY (Ishizaki et al. 2013). Recently, a fluorescence-based assay for WecA activity has been developed and used to screen compound libraries with some success (Mitachi et al. 2016). Inhibitors targeting WbbL have yet to be identified. This essential enzyme, present in all mycobacteria, is recognized as a promising target and efforts are underway to characterize the enzyme via the establishment of a microtiter plate-based assay for its activity, which could be exploited in inhibitor library screening (Grzegorzekwicz et al. 2008).

The linker unit provides an attachment point for the polymerization of the galactan chain. This process also occurs in the cytoplasm. The bifunctional galactofuranosyltransferases (GlfT1 and GlfT2) (Alderwick et al. 2008) are responsible for the synthesis of the linear galactan chain. Initially, GlfT1 transfers Gal\(\beta\) from UDP-Gal\(\beta\) to the C-4 position of L-Rha, and then adds a second Gal\(\beta\) residue to the C-5 position of the primary Gal\(\beta\), generating C\(\alpha\)-P-P-GlcNAc-L-Rha-Gal\(\beta\) (Mikusova et al. 2006; Alderwick et al. 2008; Belanova et al. 2008). GlfT2 sequentially transfers Gal\(\beta\) residues to the growing galactan chain with alternating \(\beta\) (1 \(\rightarrow\) 5) and \(\beta\) (1 \(\rightarrow\) 6) glycosidic linkages (Kremer et al. 2001a; Rose et al. 2006). The galactan chains contain \(\sim\)30 Gal\(\beta\) residues in vivo, forming C\(\alpha\)-P-P-GlcNAc-L-Rha-Gal\(\beta\) (Daffe et al. 1990), but the chain length determination mechanism is yet to be fully understood. GlfT1 and GlfT2 are suitable targets, as rationalized by an in silico target identification program (Raman et al. 2008). UDP-Gal\(\beta\) derivatives, with modifications to the C-5 and C-6 positions have been investigated as suitable inhibitors of these enzymes, whereby they cause premature galactan chain termination (Peltier et al. 2010).

The remainder of arabinogalactan synthesis occurs on the outside of the cell. Although the transport mechanism of this cell wall polysaccharide is not fully understood, Rv3781 and Rv3783, encoding an ABC transporter, are potential ‘flipase’ candidates (Dianiskova et al. 2011). Ara\(\beta\) residues are transferred directly onto C\(\alpha\)-P-P-GlcNAc-L-Rha-Gal\(\beta\) from the lipid donor decaprenylphosphoryl-D-arabinose (DPA) (Wolucka et al. 1994). DPA is synthesized through a series of cytoplasmic steps, and originates exclusively from phospho-\(\alpha\)-D-ribosyl-1-pyrophosphate (pRPP), prior to reorientation to the extracellular...

The DPA synthetic pathway is a validated drug target. The nitro-benzothiazinones (BTZs) and the structurally related dinitrobenzamides target DprE1 and are effective against MDR and XDR strains of *Mt* with low toxicity (Christophe et al. 2009; Batt et al. 2012; Makarov et al. 2014, 2015). The success of these compounds has led to the study of the other enzymes as potential drug targets. Conditional knockdown mutants of dprE1, dprE2, ubiA, prsA and Rv3807c have proven the essentiality of all except Rv3807c, and a target-based whole-cell screen has been developed using these strains of reduced expression levels to identify enzyme-specific inhibitors. Inhibitors targeting a particular enzyme cause increased sensitivity and this was confirmed with BTZ and KRT2029 targeting DprE1 and UbiA, respectively, and can be the subject of future medicinal chemistry efforts (Kolly et al. 2014).

The mechanism of DPA reorientation into the periplasm is unknown. The "flipase" was recently considered to be Rv3789, but there is evidence that this protein plays a different role: to act as an anchor protein to recruit AftA (Kolly et al. 2015). AftA is the first arabinofuranosyltransferase (AraT), of a predicted six, to commence the addition of arabinose from DPA onto the galactan chain (Alderwick et al. 2006). AftA transfers a single Ara residue onto C-5 of β(1 6) Gal f residues 8, 10 and 12 of C50-P-P-GlcNAc-L-Rha-Gal f30 (Alderwick et al. 2005). EmbA and EmbB, so called because their discovery was based on the mode of action elucidation of ethambutol (EMB), catalyse the addition of further α(1 3) Araf polymerization (Alderwick et al. 2005). AftC introduces α(1 3) branching (Birch et al. 2008), with AftD having an equivalent role (Skovierova et al. 2009). The structure terminates in a well-defined hexa-arabinofuranosyl (Araf6) structural motif: [β-D-Araf-(1 2)-α-D-Araf3,3,5-α-D-Araf-(1 5)-α-D-Araf] 6. This motif is generated by EmbA, EmbB, AftC, AftD and AftB (Escuyer et al. 2001; Alderwick et al. 2005; Birch et al. 2008, 2010; Skovierova et al. 2009). AftB catalyses the transfer of the terminal β(1 2) Araf residues (Seidel et al. 2007). C-5 of the terminal β-D-Araf and the penultimate 2-α-D-Araf of this motif act as anchoring points for mycolic acids (McNeil et al. 1991).

The Emb arabinosyltransferases are inhibited by EMB, a well-recognized anti-TB drug, which is employed in the short-course treatment strategy of TB. Efforts are focused on investigating EMB analogues, such as SQ109 (Jia et al. 2005a, b, c; Saacksteder et al. 2012) and SQ775 (Bogatcheva et al. 2006), for future lead drug development. Interestingly, the other AraTs are not inhibited by EMB (Alderwick et al. 2006; Seidel et al. 2007; Birch et al. 2008) and screening for inhibitors against these enzymes is hindered due to the nature of the protein and substrate (membrane bound). However, there have been reports on the development of DPA analogues for the inhibition of arabinogalactan biosynthesis (Pathak et al. 2001; Owen et al. 2007). A recent study employing a cell free assay approach with membrane preparations has determined that various DPA analogues are able to limit the incorporation of a radiolabelled DP[14C]A (Zhang et al. 2011).

The primary structure of arabinogalactan is completed by the transfer of succinyl and D-GalN residues to the inner arabinan units. PpgS, polypropenyl-phospho-N-acetylglactosaminyl synthase, catalyses the formation of polypropenyl-P-D-GalNAc from polypropenyl-P and UDP-GalNAc, which is then translocated across the membrane (Skovierova et al. 2010; Rana et al. 2012). The deacylation to polypropenyl-P-D-GalN occurs in an undetermined location and by an unknown mechanism. The glycosyltransferase, Rv3779, transfers D-GalN to arabinogalactan at the C-2 position of 3,5-branched Araf residue (Scherman et al. 2009; Skovierova et al. 2010; Peng et al. 2012; Rana et al. 2012). Succinylated Araf residues have also been detected at this position of non-mycolated arabinan chains (Bhamidi et al. 2008), but the enzyme responsible is currently unknown. A comprehensive mechanistic and functional understanding of these enzymes is required for evaluation as suitable drug targets and to date, there are no identifiable inhibitors against these processes. The final stage is the attachment of the arabinogalactan macromolecule to peptidoglycan. The enzyme responsible for this essential ligation has recently been elucidated to be Lcp1 (Harrison et al. 2016).
membranes of the cell wall via the phosphatidyl-
myo-inositol unit (Ortalo-Magne et al. 1996) (Fig. 1). The core structure of PIM consists of an
acylated sn-glycerol-3-phospho-(1-D-
myo-inositol), the phosphatidyl inositol (PI) unit. Glycosylation with mannopyranose (Manp) residues at the O-2 and O-6 positions of myo-inositol, results in the
mannosyl phosphate inositol (MPI) anchor (Ballou et al. 1963; Ballou and Lee, 1964; Nigou et al. 2004). The MPI structure is highly diverse, with variations in the type (commonly palmitic and
tuberculostearic chains (Pitarque et al. 2005)), number and location of acyl chains. The most preva-
lent forms of PIMs in mycobacteria are tri- and
tetra-acylated phospho-
myo-inositol di/hexamannos-
ides (Ac1PIM2, Ac1PIM6, Ac2PIM2, Ac2PIM6), where in the hexamannosides, there is one Manp
unit on the O-2 and five Manp units on the O-6 position of myo-inositol (Gilleron et al. 2001). Extensions of mannann and arabinomannann chains on the MPI anchor form LM and LAM, respect-
ively. In both LM and LAM, the manann chain consists of approximately 21–34 α(1→6) linked Manp
units, decorated with single α(1→2)-Manp residues (Kaur et al. 2008). In LAM, the manann chain is
glycosylated through an α(1→2) linkage with
∼50–80 Araf residues (Kho et al. 1996).
In mycobacteria, PI and PIMs contribute up to
56% of all phospholipids in the cell wall and 37%
in the cytoplasmic membrane (Goren, 1984).
These significant quantities indicate their import-
ance. Not only are they structural components, they also have roles in cell wall integrity, permea-

biosynthesis of phosphatidyl-
myo-inositol mannosides, lipomannan
and lipoarabinomannan
PIM biosynthesis begins in the cytoplasm (Fig. 4). The α-mannopyranosyl transferase (Manp/T), PimA, of the GT-A/B superfamily, transfers Manp from the donor GDP-Manp to position O-2 of the
myo-inositol ring to form PIM₁ (Kordulakova et al. 2002; Guerin et al. 2007). A second Man₆p residue is transferred to position O-6 of the myo-inositol ring by PimB to form PIM₂ (Guerin et al. 2009). Acylation of the Man₆p residue of PIM₂ is performed by the acyltransferase Rv2611c before or after the addition of the second Man₆p residue (Kordulakova et al. 2003). The acylation of the C-3 position of the myo-inositol ring is performed by an unknown acyltransferase. This finishes the synthesis of the MPI anchor. Mannosylation of Ac₁/Ac₂PIM₃ to Ac₁/Ac₂PIM₅ is performed by a Man₆pT, designated PimC, but this enzyme is yet to be confirmed in Mtb H37Rv (Kremer et al. 2002b). It is suspected that the subsequent addition of Man₆p to the non-reducing end of Ac₁/Ac₂PIM₅ is performed by the unidentifed PimC or PimD forming Ac₁/.Ac₂PIM₆.

The Man₆pTs have been the subject of target-based screening programs. More specifically, in vitro PimA activity was screened with approximately 350 compounds. Several hit molecules exhibited significant inhibition, but the compounds did not exhibit in vivo activity in Mtb (Sipos et al. 2015). Substrate analogues of PimA and PimB, galactose-derivived phosphonate analogs of PI, have also been developed, which show enzyme inhibition in a cell-free system (Dinev et al. 2007).

The biosynthesis of Ac₁/.Ac₂PIM₄ marks the transition towards the synthesis of higher order PIMs, LM and LAM (Fig. 4). It is predicted that the synthesis of Ac₁/Ac₂PIM₄ occurs on the cytoplasmic side of the membrane, and at this point, is flipped across the membrane by an unidentified translocase, with the remainder of the steps thought to occur in the periplasmic space. The integral membrane Man₆pTs (of the GT-C glycosyltransferase superfamily) are reliant on polyprenyl-phosphate-based mannose donors (PPM) rather than the nucleotide-based sugars (Berg et al. 2007). The polyprenyl monophosphomannose synthase, Ppm1, catalyses the synthesis of PPM from GDP-Man₆p and polyprenyl phosphates (Gurcha et al. 2002).

PimE catalyses the transfer of an α(1→2)-linked Man₆p residue onto Ac₁/Ac₂PIM₄, generating Ac₁/Ac₂PIM₅ (Morita et al. 2006). The transfer of the last Man₆p residue is either performed by PimE or by an unidentified GT-C glycosyltransferase forming Ac₁/Ac₂PIM₆ (Morita et al. 2006). The distal 2-linked Man₆p residues are not present in the mannan core of LM or LAM; Ac₁/Ac₂PIM₄ is the likely precursor for the extension of the mannan chain. Recent evidence suggests that the putative lipoprotein LpqW channels intermediates such as Ac₁/Ac₂PIM₄ towards either PimE (to form the polar lipids) or to LM and LAM synthesis (Crellin et al. 2008). The mannosyltransferases, MptA and MptB (Mishra et al. 2007, 2008), are responsible for the α(1→6)-linked mannan core of LM and LAM. MptC catalyses the transfer of the monomannose side chains via α(1→2) linkages, forming mature LM (Kaur et al. 2008; Mishra et al. 2011). Modification of LM leads to LAM. Approximately 50–80 Ara₆p residues are added using DPA as the donor, comparable to that of the arabinogalactan domain. An unidentified Ara₆pT primes the mannan chain, which is further elongated by EmbC, adding 12–16 Ara₆p residues with α(1→5) linkages (Shi et al. 2006; Alderwick et al. 2011a). AftC, the same enzyme involved in arabinogalactan synthesis, integrates α(1→3) Ara₆p branches (Birch et al. 2008). It has also been speculated that AftE introduces α(1→3) Ara₆p, but its function is yet to be confirmed (Skovierova et al. 2009). The arabinan domain is terminated by β(1→2) Ara₆p linkages, predicted to be performed by AftB, resulting in branched hexa-arabinoside or linear tetra-arabinoside motifs. Further structural heterogeneity is introduced by capping motifs. These motieties consist of a number of α(1→2)-linked Man₆p residues, producing mannosylated LAM (ManLAM) (Kaur et al. 2008). Using PPM, the α(1→5) Man₆pT, CapA, attaches the first Man₆p residue (Dinadayala et al. 2006). MptC catalyses the addition of subsequent α(1→2) Man₆p residues (Kaur et al. 2008), which can be decorated with an α(1→4)-linked 5-deoxy-5-methyl-thio-xylofuranose (MTX) residue (Ludwiczak et al. 2002; Turnbull et al. 2004). The enzymes involved in the addition of MTX and succinyl residues to LAM are still to be determined.

The essentiality of PPM in lipoglycan biosynthesis makes Ppm1 an attractive drug target. Amphomycin, a lipopeptide antibiotic, inhibits the synthesis of PPM by sequestering the polyprenyl phosphates, and consequently inhibits the extracellular Man₆pTs (Banerjee et al. 1981; Besra et al. 1997). Guy et al. (2004) designed a variety of prenyl-based photoactivable probes. Upon photactiviation, a number of the probes exhibited inhibitory activity against Mtb Ppm1 and M. smegmatis α(1→6) Man₆pTs (Guy et al. 2004). Substrate analogues of the Man₆pTs have been designed to investigate enzyme–substrate interactions and mechanisms of action (Brown et al. 2001; Tam and Lowary, 2010). These types of studies will provide an invaluable insight into the interactions involved and for the future design of inhibitors.

**MYCOLIC ACIDS**

The final distinctive component of the mycobacterial cell wall is the unique fatty acids, termed the mycolic acids (Fig. 1). These unique long chain α-alkyl-β-hydroxy fatty acids (comprised a meromycolate chain of C₁₂–C₁₄ and a long saturated α-chain C₂₄–C₂₆) are attached to the arabinogalactan layer, but also make up other outer cell envelope lipids such as trehalose mono/di-mycolates and glucose
monomycolate. There are three subclasses of mycolic acids: α-mycolates, containing cyclopropane rings in the cis-configuration; methoxy-mycolates and keto-mycolates containing methoxy or keto groups, respectively, and have cyclopropane rings in the cis- or trans-configuration (Brennan and Nikaido, 1995; Watanabe et al. 2001, 2002). Mycolic acids contribute to the permeability of the cell wall, and as such are essential for cell viability, and are also essential in virulence, making the biosynthesis of mycolates suitable drug targets (Liu et al. 1996).

**MYCOLIC ACID BIOSYNTHESIS**

Mycolic acid biosynthesis occurs in the cytoplasm, involving two distinct pathways, termed fatty acid synthase types I and II (FAS I and FAS II) (Fig. 5). FAS I (Rv2524c), a multifunctional polypeptide, generates short-chain fatty acyl-CoA esters that can either form the saturated α-branch (C24), or be extended by FAS II to form the meromycolate chain (Cole et al. 1998). Elongation of the fatty acids is dependent on the availability of holo-AcpM, an acyl carrier protein, and malonyl-CoA. FabD, the malonyl-AcpM transacylase generates malonyl-AcpM (Kremer et al. 2001). C14-CoA primers from FAS I are condensed with malonyl-AcpM, catalysed by FabH (β-ketoacyl ACP synthase) (Choi et al. 2000), forming a pivotal link between the FAS I and FAS II pathways. The C16-AcpM formed is channeled to the FAS II pathway (Bhatt et al. 2007), where it undergoes a round of keto-reduction, dehydration and enoyl-reduction, catalysed by: MabA, a β-ketoacyl-AcpM reductase (Marrakchi et al. 2002); HadAB/BC, a β-hydroxyacyl-AcpM hydratase (Sacco et al. 2007); InhA, an enoyl-AcpM reductase (Banerjee et al. 1994). Successive cycles ensue, whereby the condensation reaction of FabH is replaced by the activities of KasA and KasB, β-ketoacyl synthases (Schaeffer et al. 2001; Kremer et al. 2002a). The AcpM-bound acyl chain extends by two carbon units in each cycle, forming a saturated long-chain meromycolate of C42–C62, which is subject to modifications such as cis-/trans-cyclopropanation, and the addition of methoxy and keto groups (Dubnau et al. 2000; Glickman et al. 2000; Glickman, 2003; Barkan et al. 2010). FabD32, a fatty acyl-AMP ligase, activates the meromycolate chain (Trivedi et al. 2004) and the subsequent meromycoceryl-AMP is linked with the α-alkyl-CoA ester, catalysed by Pks13, to generate a α-alkyl-β-keto-mycolic acid (Gande et al. 2004; Portevin et al. 2004). Finally a reduction step, catalysed by Rv2509, generates a mature mycolate (Bhatt et al. 2008). Transport of the mycolates to either the cell envelope or for attachment to arabino-galactan remains to be elucidated. It is considered that

---

**Fig. 5.** Inhibitors targeting mycolic acid biosynthesis. The enzymes involved in the mycolic acid biosynthetic pathway are presented. Reported inhibitors are shown in red. ‘R’ represents an acyl chain of varying carbon units in length.
the mycolates are transported in the form of trehalose monomycolate (TMM). In the generation of TMM, Takayama et al. (2005) propose that a mycolyltransferase transfers the mycolyl group from mycolyl-Pks13 to D-mannopyranosyl-1-phosphoheptaprenol (Besra et al. 1994). The mycolyl group of mycolyl-D-mannopyranosyl-1-phosphoheptaprenol is transferred to trehalose-6-phosphate by a second mycolyltransferase, forming TMM-phosphate. The phosphate moiety is removed by a trehalose-6-phosphate phosphatase, and the TMM is immediately translocated out of the cell using a resistance-nodulation-division (RND) family of efflux pumps, termed mycobacterial membrane proteins large (MmpL), limiting TMM accumulation in the cytoplasm (Takayama et al. 2005; Grzegorzewicz et al. 2012; Varela et al. 2012).

Finally, the mycolyltransferase Antigen 85 complex, formed of Ag85A, Ag85B and Ag85C, attaches the mycolic acid moiety from TMM to arabinogalactan (Jackson et al. 1999). This complex also catalyses the formation of trehalose dimermycolate, TDM, from two TMM molecules with the release of trehalose (Takayama et al. 2005). TDM, or ‘cord factor’, is implicated in the pathogenicity of Mtb.

The enzymes involved in mycolic acid biosynthesis are the targets of numerous inhibitors. In 1952, shortly after its discovery, isoniazid (INH) was administered as a front-line and essential anti-tubercular agent in the treatment of TB (Medical Research Council, 1952) and has only recently had the mode of action elucidated. Initially thought to target KatG due to mutations in the corresponding gene in resistant isolates (Zhang and Young, 1994; Rouse and Morris, 1995), INH was later revealed to be a pro-drug, with the true target being InhA (Banerjee et al. 1994; Larsen et al. 2002). Ethionamide, a structural analogue of INH, also requires cellular activation via EthA, before targeting InhA (Banerjee et al. 1994). Direct inhibitors of InhA that do not require activation are now being searched for (Lu et al. 2010; Vilcheze et al. 2011; Pan and Tonge, 2012; Encinas et al. 2014; Manjunatha et al. 2015; Sink et al. 2015; Martinez-Hoyos et al. 2016). One such molecule is the broad-spectrum antibiotic triclosan, which has not been adopted in TB treatment due to its sub-optimal bioavailability (Wang et al. 2004). In the last year, GlaxoSmithKline have published a set of thiadiazole compounds, which directly target InhA, with GSK693 demonstrating in vitro efficacy comparable to INH (Martinez-Hoyos et al. 2016).

Therefore, old drug targets should not be discounted in the search for new anti-tubercular agents.

The β-ketoacyl synthases, KasA and KasB, are the targets of the natural products cerulenin (Parrish et al. 1999; Schaeffer et al. 2001; Kremer et al. 2002a), platsensimycin (Brown et al. 2009), and thiolaactomycin (TLM) (Kremer et al. 2000; Schaeffer et al. 2001). There has been significant interest in TLM due to its broad-spectrum activity and numerous analogues have been synthesized to improve on potency and pharmacokinetic properties (Kremer et al. 2000; Senior et al. 2003, 2004; Kim et al. 2006). The biphenyl-based 5-substituents of TLM also exhibit in vitro activity against FabH, but with no whole-cell activity (Senior et al. 2003, 2004). The 2-tosyl-naphthalene-1,4-diol pharmacophore of TLM also has in vitro activity against FabH, however, whole-cell data are yet to be published (Alhamadsheh et al. 2008). Recently, a new anti-TB compound, an indazole sulfonamide GSK3011724A, was discovered from a phenotypic whole-cell HTS (Abrahams et al. 2016). The compound was shown to target KasA specifically, with no discernable target engagement with KasB or FabH, and is currently the focus of medicinal chemistry optimization (Abrahams et al. 2016).

Due to the success of InhA as a chemotherapeutic target, there is a mounting interest in the other enzymes involved in mycolic acid biosynthesis from a drug target perspective that could bypass INH resistance in MDR and XDR-TB. Formerly used in the treatment of TB, the thiocarbamide-containing drugs, thiacetazone and isoxyl, were shown to target mycolic acid biosynthesis and the inhibition mechanism has recently been elucidated. Following activation by EthA, both drugs target the HadA subunit of the HadABC dehydratase, forming a covalent interaction with the active site cysteine (Grzegorzewicz et al. 2015). It has also been shown that thiacetazone inhibits cyclopropanation of mycolic acids (Alahari et al. 2007). MabA has been the subject of a molecular docking study. Comparable with the control inhibitor substrate isonicotinic-acyl-NADH, pteleoellagic acid had a high docking score with in vitro activity to be confirmed (Shilpi et al. 2015). Through a target-based screening approach linked with whole-genome sequencing of resistant mutants, a benzofuran has been shown to target Pks13 (Ioerger et al. 2013). Additionally, Pks13 is the target of thiophene compounds (Wilson et al. 2013) including 2-aminothiophenes (Thanna et al. 2016). From a GFP reporter-based whole-cell HTS, a diarylcoumarin exhibited potent activity against Mtb and this structural class was shown to target FabD32 by inhibiting the acyl–acyl carrier protein synthetase activity (Stanley et al. 2013). The homologue of the Rv2509 complex in M. smegmatis is non-essential but loss of function increases susceptibility to lipophilic antibiotics such as rifampicin. Targeting this ‘secondary’ drug target in Mtb could increase the susceptibility of the bacilli to antibiotics (Bhatt et al. 2008). The Antigen 85 complex has been the focus of a number of inhibitor-based screening studies (Belisle et al. 1997; Gobec et al. 2004; Sanki et al. 2008, 2009; Elamin et al. 2009; Barry et al. 2011). Recently, an inhibitor from a compound library was shown to bind to Antigen 85C, and derivatives of this compound...
have been synthesized, with 2-amino-6-propyl-4,5,6,7-tetrahydro-1-benzothiphene-3-carbonitrile (I3-AG85) exhibiting the lowest MIC in Mtb and drug-resistant strains (Warrier et al. 2012).

In the target identification of new anti-tubercular compounds, some targets can be regarded as promiscuous, inhibited by multiple different chemical scaffolds, exemplified by MmpL3 (Grzegorzewicz et al. 2012; La Rosa et al. 2012; Stanley et al. 2012; Tahlan et al. 2012; Lun et al. 2013; Remuinan et al. 2013), a predicted TMM transporter. Through the generation and sequencing of spontaneous resistant mutants, a number of inhibitors with diverse chemical structures have been shown to target MmpL3 (Grzegorzewicz et al. 2012; La Rosa et al. 2012; Stanley et al. 2012; Tahlan et al. 2012; Lun et al. 2013; Remuinan et al. 2013). However, a recent chemoproteomics approach determined that one of the proposed inhibitor classes of MmpL3, the tetrahydropropyrazo[1,5-a]pyrimidine-3-carboxamides (THPPs), has a novel alternative target, EchA6 (Cox et al. 2016). Sequence analysis predicted EchA6 to be an enoyl-CoA hydratase, but it lacks the residues required for catalytic activity. Through an extensive biochemical investigation, Cox et al. (2016) predicted that EchA6 shuttles fatty acyl-CoA esters from the β-oxidation pathway into FAS II, ready for the condensation activities of KasA or KasB with malonyl-AcpM. This research demonstrates that target identification of inhibitory compounds can unveil not only a new biological pathway, but also an untapped area for drug targets.

**Drug Discovery Efforts**

The strategies involved in drug discovery are forever evolving. Traditional enzyme screening campaigns and medicinal chemistry focused on ligand-based inhibitor designs (such as substrate or transition state analogues) that once dominated drug discovery are being superseded by phenotypic HTS. The former approach often relies on the X-ray crystal structure of the enzyme or biochemical understanding, and successful inhibitors from these screens are further challenged by target engagement in *vivo*. Over recent years, HTS has become the lead approach in drug discovery. HTS employs extensive compound libraries of diverse chemical structures, and as a consequence, these methods can identify a multitude of inhibitors with novel chemical scaffolds. Phenotypic HTS can reveal anti-TB agents with whole-cell activity and unknown modes of action, having the potential to unveil new biochemical pathways (Abrahams et al. 2012, 2016; Gurcha et al. 2014; Mugumbute et al. 2015). Alternatively, phenotypic HTS can be target-based, focusing on enzymes or pathways such as those involved in cell wall biosynthesis. This can be a very effective way to identify novel anti-TB compounds with known modes of action, but is limited by the specified target (Batt et al. 2015; Martinez-Hoyos et al. 2016). Target assignment is a fundamental step in the drug discovery pipeline. Without knowledge of the physiological target, efforts can be wasted on developing compounds against an unsuitable target, such as those homologous in humans. Establishing the mode of action of an inhibitor is a prerequisite for facilitating medicinal chemistry efforts to convert compounds into potential drug candidates.

**Concluding Remarks**

The essential mycobacterial cell wall, responsible for structural integrity, permeability and pathogenicity, is an attractive drug target, both structurally and biosynthetically. Recent advancements in biochemical and omics-based techniques have led to the discovery and mechanistic understanding of enzymes involved in mycobacterial cell wall synthesis and assembly. Although a number of key enzymes are yet to be established, there are a plethora of suitable targets, exploited not only in current treatment programmes but also for anti-TB drug discovery. In the current TB treatment regimen, two of the front-line drugs, INH and EMB, target mycolic acid and arabinogalactan biosynthesis, respectively, with the second-line drugs such as ethionamide and D-cycloserine also targeting cell wall production. The proven success of these drugs validates the future development of inhibitors targeting the unique mycobacterial cell wall, which remains a source of unexploited clinically relevant drug targets. The continued progression in drug discovery approaches and the optimization of biochemical techniques, will enable the rapid identification of anti-TB agents, many of which are likely to target the biosynthesis of the so-called ‘Achilles heel’ of Mtb.

**Acknowledgements**

The authors would like to thank Jonathan Cox for his technical support and advice.

**Financial Support**

G.S.B. acknowledges support in the form of a Personal Research Chair from Mr James Bardrick, a Royal Society Wolfson Research Merit Award, the Medical Research Council (MR/K012118/1) and the Wellcome Trust (081569/Z/06/Z).

**References**


Myobacterial cell wall biosynthesis

(2016). LpdL is a phosphotransferase responsible for ligating arabino-galactan to peptidoglycan in Mycobacterium tuberculosis. American Society for Microbiology 7, e00972.


Huang, J., Coward, L., Gorman, G. S., Noker, P. E. and Tomaszewski, J. E. (2005a). Pharmacoproteomic effects of isoniazid, ethambutol, and N-

Huang, J., Coward, L., Gorman, G. S. and Tomaszewski, J. E. (2005b). Pharmacoproteomic effects of isoniazid, ethambutol, and N-


Jiang, H., Njoku, H. I., Barry, C. E., III and Jackson, M. (2010). Assessment of the essentiality of the decaprenyl-phospho-


Kremer, L., Lejeune, M., Beli, I., Coisse, J., Chatterjee, D., Brennan, P. J. and Besra, G. S. (2002c). Mycolic acid biosynthesis and enzymatic charac-


Mycobacterial cell wall biosynthesis


Wang, L. Q., Falany, C. N. and James, M. O. (1987). Effects of moenomycin on Escherichia coli. Journal of General Microbiology 133, 54.70.40.11


